Guizhou Bailing Group Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002424.SZ

Guizhou Bailing Group Pharmaceutical Co., Ltd. Net Income for the year ending December 31, 2023: USD -58.38 M

Guizhou Bailing Group Pharmaceutical Co., Ltd. Net Income is USD -58.38 M for the year ending December 31, 2023, a -390.96% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Guizhou Bailing Group Pharmaceutical Co., Ltd. Net Income for the year ending December 31, 2022 was USD 20.07 M, a 7.61% change year over year.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Net Income for the year ending December 31, 2021 was USD 18.65 M, a -20.12% change year over year.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Net Income for the year ending December 31, 2020 was USD 23.34 M, a -42.51% change year over year.
Guizhou Bailing Group Pharmaceutical Co., Ltd. Net Income for the year ending December 31, 2019 was USD 40.60 M, a -50.42% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Shenzhen Stock Exchange: 002424.SZ

Guizhou Bailing Group Pharmaceutical Co., Ltd.

CEO	Mr. Min Niu
IPO Date	June 3, 2010
Location	China
Headquarters	Eco & Tech Dev Zn
Employees	6,582
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Guizhou Bailing Group Pharmaceutical Co., Ltd. researches, develops, produces, and sells Chinese medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, pills, powders, tinctures, sprays, and ointments for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases. Guizhou Bailing Group Pharmaceutical Co., Ltd. was founded in 2005 and is based in Anshun, China.

Key trends

Past 5 years